Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
Key Highlights
- ➤BELLA triplet delivered 7.2-month median PFS in 95 platinum-resistant patients
- ➤BELLA objective response rate reached 59% with Lifyorli triplet
- ➤Bevacizumab-naive patients achieved 8.1-month median PFS
- ➤BELLA six-month overall survival reached 88%; median OS was not reached
- ➤No new safety signals emerged; adverse events matched known treatment profiles
Expert Statements
Domenica Lorusso, Director of the Gynaecological Oncology Unit at Humanitas Hospital San Pio X, Milan, and Full Professor of Obstetrics and Gynaecology, Humanitas University, Rozzano
“Following ROSELLA’s outstanding results, these BELLA data provide valuable insight into adding bevacizumab to the Lifyorli/nab-paclitaxel treatment backbone. These findings help advance our understanding of both the efficacy and safety profile of this triplet combination as we work to expand treatment options for patients.”
Bill Guyer, Chief Development Officer of Corcept Therapeutics
“Our goal is to demonstrate our proprietary selective GR antagonists’ ability to benefit patients with a wide array of solid tumors, in combination with many different anti-cancer agents. These results provide more evidence of GR antagonism’s versatility – in this case, of Lifyroli’s potential to benefit patients when combined with nab-paclitaxel and bevacizumab, whether or not bevacizumab had been included in a patient’s prior treatment regimen. We look forward to presenting the full BELLA Part A data next year.”
Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli(®) Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
* Lifyorli (relacorilant) in combination with nab-paclitaxel and bevacizumab demonstrated clinically meaningful progression-free survival (PFS), objective response rate (ORR) and overall survival (OS), with the more pronounced results being in patients who had no prior treatment with bevacizumab.
Get started
Create a free account to read the full story.